Armada to combine with Brains Bioceutical in $750m deal
Brains Therapeutics intends to list its common shares on the Nasdaq stock exchange under the ticker symbol BAPI.
Drug Development
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Evommune signs $1.1bn licence deal with Hinova for EVO570
PharmatrophiX and Circular partner on neurodegenerative drugs
GEBRO and Spektus sign collaboration for ActraFlex
FDA to review uniQure’s BLA for Huntington’s gene therapy
Inovio’s Voceryq receives FDA accelerated approval for RRP
Dren Bio raises $350m for dibotatug clinical development
